Article Text


Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity
  1. G Vaudo1,
  2. S Marchesi1,
  3. R Gerli2,
  4. R Allegrucci2,
  5. A Giordano2,
  6. D Siepi1,
  7. M Pirro1,
  8. Y Shoenfeld3,
  9. G Schillaci1,
  10. E Mannarino1
  1. 1Internal Medicine, Angiology and Arteriosclerosis, University of Perugia School of Medicine, Perugia, Italy
  2. 2Internal Medicine and Oncological Sciences, University of Perugia School of Medicine, Perugia, Italy
  3. 3Department of Medicine B, and Centre for Autoimmune Diseases, Chaim Sheba Medical Centre, Tel-Hashomer, Israel
  1. Correspondence to:
    Dr G Vaudo
    Unit of Internal Medicine, Angiology and Arteriosclerosis, Department of Clinical and Experimental Medicine, University of Perugia School of Medicine, via Brunamonti, 51-06122 Perugia, Italy;


Background: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease. Endothelial dysfunction represents the earliest stage of atherosclerosis.

Objective: To evaluate the influence of chronic inflammatory state on endothelial function in patients with RA by measuring endothelial reactivity in young patients with RA with low disease activity and without traditional cardiovascular risk factors.

Methods: Brachial flow mediated vasodilatation (FMV), assessed by non-invasive ultrasound, was evaluated in 32 young to middle aged patients with RA (age ⩽59 years), with DAS28 ⩽3.2 and without overt cardiovascular disease, and in 28 age and sex matched controls.

Results: Mean (SD) FMV was significantly lower in patients than in controls (3.2 (1.3)% v 5.7 (2.0)%; p<0.001), inversely related to low density lipoprotein cholesterol (r = −0.45, p<0.05) and C reactive protein (CRP), expressed as the value at the moment of ultrasound evaluation (r = −0.44, p<0.05), as the average of CRP levels evaluated at different times during the disease (r = −0.47, p<0.05), or as the average of ⩾4 determinations multiplied by the disease duration (r = −0.40, p<0.05). In a multivariate regression model, a lower brachial flow mediated vasodilatation was independently predicted by low density lipoprotein cholesterol (β = −0.40, p<0.05), average CRP levels multiplied by the disease duration (β = −0.44, p<0.05), and brachial artery diameter (β = −0.28, p<0.05).

Conclusions: Young to middle aged patients with RA with low disease activity, free from cardiovascular risk factors and overt cardiovascular disease, have an altered endothelial reactivity that seems to be primarily related to the disease associated chronic inflammatory condition.

  • rheumatoid arthritis
  • endothelial function
  • flow mediated vasodilatation
  • C reactive protein
  • CRP, C reactive protein
  • DAS, Disease Activity Score
  • FMV, flow mediated vasodilatation
  • HDL, high density lipoprotein
  • LDL, low density lipoprotein
  • RA, rheumatoid arthritis
  • RF, rheumatoid factor

Statistics from

Rheumatoid arthritis (RA) is characterised by a high cardiovascular mortality, which exceeds that of the general population.1–4 About 50% of atherosclerotic coronary artery disease in the community occurs in the absence of “traditional” cardiovascular risk factors, including male sex, family history for cardiovascular disease, age, dyslipidaemia, arterial hypertension, diabetes mellitus, smoking, and obesity.5 Increasing evidence suggests a key role of inflammation in the onset and progression of atherosclerosis.6 Experimental studies have shown that several inflammatory mediators, including activated leucocytes, cytokines, and C reactive protein (CRP), have an active role within the atherosclerotic plaques.7,8 Moreover, some large scale prospective epidemiological studies have shown that high serum levels of inflammatory markers, such as CRP, are predictive of future cardiovascular events.9–12

Altered function of the arterial endothelium is currently considered the earliest stage of the development of the atheroma. Endothelial dysfunction is also recognised as a promoter of the disease progression and a trigger of cardiovascular events. It may be detected as an impaired ability of the artery to dilate in response to a variety of physical and chemical stimuli, as a consequence of a reduced nitric oxide bioavailability.13 Ultrasonographic determination of arterial vasodilatation after post-occlusion reactive hyperaemia (flow mediated vasodilatation (FMV)) is an accurate and reproducible non-invasive method for evaluating endothelial function in humans.14

Endothelial dysfunction has been recently described in patients with RA with high inflammatory activity,15–17 and an improvement in endothelial function has been observed after treatment with disease modifying antirheumatic drugs.15,16 Similar findings were reported after treatment of patients affected by primary systemic necrotising vasculitis.18 Although these findings support the notion that acute systemic inflammation favours altered endothelial reactivity, it is unknown whether a chronic inflammatory condition, such as RA, leads to the impairment of endothelial function, independently of disease flares.

This study aimed at evaluating the influence of chronic inflammatory state on endothelial function in patients with RA. For this purpose, brachial artery FMV was measured in young patients with RA with low disease activity and without conventional cardiovascular risk factors.


Thirty two consecutive young patients (four men, 28 women; aged ⩽59 years, mean age 50 (7) years, range 27–59) meeting the American College of Rheumatology criteria for classification of RA.19 were enrolled from our outpatient clinic. The mean (SD) disease duration was 11 (8) years. Twenty eight subjects matched for age and sex acted as controls: 8 with fibromyalgia, 10 with knee osteoarthritis, and 10 with hand osteoarthritis.

All subjects underwent a detailed clinical global examination that also included measurement of height and weight. Disease activity was measured by the Disease Activity Score (DAS28), a validated score including tender and swollen joint count, erythrocyte sedimentation rate, and a patient global assessment of disease activity.20 Only patients with low disease activity (DAS28 ⩽3.2) were enrolled into the study. In addition, patients and controls were excluded if they had a family history of premature (<55 years in men, <65 years in women) coronary artery disease in a first degree relative, or if they were smokers or had stopped smoking for less than two years. We also excluded subjects with hypertension (defined by blood pressure ⩾150/90 mm Hg or using antihypertensive drugs), diabetes mellitus (defined according to the World Health Organisation criteria),21 history of hyperlipidaemia or obesity (body mass index <30 kg/m2), angina, previous myocardial infarction or stroke, active infectious diseases, kidney failure, neoplasms, or other connective tissue diseases.

In all subjects, blood was drawn in the morning after 13 hours’ fasting, and the following variables were determined: erythrocyte sedimentation rate, rheumatoid factor (RF), and CRP (laser nephelometry), total cholesterol, triglycerides (enzymatic colorimetric method), high density lipoprotein (HDL) cholesterol (enzymatic colorimetric method after precipitation to polyethylene glycol), low density lipoprotein (LDL) cholesterol (Friedewald formula), and homocysteine (high performance liquid chromatography). Serum CRP concentration was determined as the level at the moment of the ultrasound examination (actual CRP). Then, to quantify the degree of inflammation over time in each patient, the average of CRP levels evaluated at different times during the disease (at least four determinations/year) was determined (average CRP) and this value was multiplied by the disease duration in years (CRP duration). All subjects were classified as RF+ or RF− on the basis of the presence or absence of RF in the serum, respectively. Twenty of the patients were receiving methotrexate (⩽15 mg/week) plus regular folic acid supplementation of 7.5 mg/week, 13 were being treated with prednisone (⩽5 mg/day), 6 with hydroxychloroquine (200 mg/day), 2 with azathioprine (100 mg/day), and 2 with sulfasalazine (2 g/day). Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, were discontinued in all patients at least 30 days before vascular examination. The study protocol was approved by the ethical committee of our institution, and written consent was obtained from all subjects included in the study.

FMV was assessed on the brachial artery by ultrasonography. Any drug known to affect endothelial function, including nitrates, hypolipidaemic drugs, and aspirin, was withdrawn ⩾1 week before the examination. Details of the procedure, which was performed according to the International Brachial Artery Reactivity Task Force guidelines,14 have been reported elsewhere.22 Briefly, the measurements were performed in supine position on the non-dominant arm, after 10–20 minutes’ resting in a quiet, dark room with a temperature of 22°C. The brachial artery was scanned longitudinally just above the antecubital crease using a 10 MHz probe (HDI 3500, Advanced Technology Laboratories). The diameter of the brachial artery was measured at the R wave of the electrocardiogram, on the interface between the media and adventitia of the anterior and posterior wall. Gain settings were optimised to identify the lumen and the vessel wall interfaces, and were not modified during the examination. Hyperaemia was induced by inflation of a pneumatic cuff (12.5 cm wide) at 230–250 mm Hg for four minutes on the most proximal portion of the upper arm. The arterial diameter measurement was repeated 45–60 seconds after sudden deflation of the cuff. Tracings were recorded on videotape and read by one investigator, who was unaware of the subject’s clinical data and temporal sequence. The average of three measurements of basal and post-hyperaemia diameter was used for the analysis. FMV was expressed as the relative increase in brachial artery diameter during hyperaemia, and defined as 100×((post-hyperaemia diameter–basal diameter)/basal diameter). Blood flow was measured as arterial cross sectional area (π×r2) times mean Doppler velocity corrected for angle. The intraobserver between-occasion reproducibility of FMV in our laboratory was assessed in 10 subjects examined two days apart. The mean (SD) difference between the two examinations was 1.0 (1.5)%.

Statistical analysis

Data are presented as mean (SD), and as median and interquartile range for CRP. Because CRP showed a non-Gaussian distribution with a significant positive skewness, data are presented after logarithmic transformation. Student’s t test was performed to compare parametric variables between cases and controls. Pearson’s correlation coefficient was used to examine the relation between brachial FMV and several study variables. Multiple linear regression analysis was performed with brachial FMV as dependent variable. The independent variables in the model were age, CRP duration after logarithmic transformation, triglycerides, HDL cholesterol, LDL cholesterol, systolic blood pressure, and brachial artery diameter. Levels of p<0.05 were considered significant. Data were stored by SPSS statistical package, release 10.0 (SPSS Inc, Chicago, Illinois, USA).


Table 1 shows the characteristics of the study group. Patients with RA had significantly higher erythrocyte sedimentation rate (26 (15) v 11 (5) mm/1st h; p<0.001), actual CRP (12 (12) v 2 (12) mg/l; p<0.001), and average CRP levels (12 (9) v 2 (1) mg/l; p<0.001) than controls. HDL cholesterol was higher in the total patient group than in controls (1.6 (0.5) v 1.3 (0.4) mmol/l; p<0.05), as well as in the two subsets of 13 subjects treated with steroids (1.7 (0.6) mmol/l; p<0.05) and 19 not treated with steroids (1.5 (0.7) mmol/l; p<0.05). Table 2 shows that the FMV of the brachial artery was significantly lower in patients than in control subjects (3.2 (1.3) v 5.7 (2.0)%; p<0.001). A similar reduction of FMV was seen when the ultrasound examination was repeated in eight patients with stable disease activity after 30 and 60 days from the first evaluation (time 0: 3.4 (1.1)% , time 30: 3.3 (1.4)%, time 60: 3.2 (1.0)%; p = NS). No significant difference in brachial artery FMV was seen between patients without and with serum RF (3.5 (0.4) v 3.7 (0.9)%, respectively; p = NS), and with or without bone erosions (3.7 (0.3) v 3.6 (0.7)%, respectively; p = NS).

Table 1

Selected clinical characteristics of 32 patients with RA and 28 healthy control subjects

Table 2

Vascular parameters of the study group

At the univariate analysis (table 3), the baseline value of FMV showed an inverse correlation with LDL cholesterol (r = −0.45, p<0.05), actual CRP (r = −0.44; p<0.05), average CRP (r = −0.47, p<0.05), and CRP duration (r = −0.48, p<0.05; fig 1). We did not find any significant correlation of FMV with age, HDL cholesterol, triglycerides, homocysteine, erythrocyte sedimentation rate, duration of disease, and systolic and diastolic blood pressure.

Table 3

Univariate correlations of flow mediated vasodilatation with selected variables in patients with RA

Figure 1

Univariate correlation between brachial artery flow mediated vasodilatation and CRP duration, expressed as average CRP in the past year multiplied by the disease duration in years.

Table 4 shows the results of the multivariate linear regression analysis in patients with RA. A lower brachial artery FMV was independently predicted by LDL cholesterol (β = −0.40, p<0.05), CRP duration (β = −0.44, p<0.05), and brachial artery diameter (β = −0.28, p<0.05). The multivariate model explained 50% of the observed variability of brachial artery FMV.

Table 4

Independent predictors of brachial artery flow mediated vasodilatation in patients with RA


The present study shows that young to middle aged patients with RA with low disease activity without clinically overt atherosclerotic disease or traditional cardiovascular risk factors have an altered pattern of brachial FMV. Endothelial dysfunction was related to serum CRP values, measured both at the moment of the study and as the average of several previous determinations. Interestingly, the average CRP level multiplied by the disease duration, a marker of the degree of inflammation over the time, was the only predictor of impaired FMV in our patients, along with LDL cholesterol.

A number of data are available about the association between connective tissue diseases and arterial endothelial function. Experimental data suggest that acute inflammation may interfere with endothelial function23 through the action of proinflammatory cytokines which can modify the vascular release of both nitric oxide24 and endothelium derived hyperpolarising factor.25 An impaired endothelial reactivity has been shown in patients with systemic lupus erythematosus,26 necrotising vasculitis,18,27 and Kawasaki disease.28 An altered endothelial function has been observed in some,16,17 but not all,15 studies investigating patients with high activity RA. One of those reports found an impaired large- and small-artery compliance in a small group of patients with RA.15 Because arterial compliance is the result of an involvement of the arterial media layer, a combined endothelium and smooth muscle cell damage rather than an isolated endothelial injury can be proposed.15 Moreover, there is initial evidence that a decrease in disease activity induced by treatment is associated with an improvement of endothelial function.16,17 These data and our own findings support the view that inflammation may have an influence on endothelial function in RA.

These data are of particular interest from a clinical point of view. Endothelial dysfunction is the earliest stage of atherosclerotic disease and the expression of a systemic phenomenon. Endothelial reactivity of the brachial artery shows a close correlation with that seen in the coronary arteries.29 Moreover, endothelial dysfunction at both the coronary30 and peripheral31 level is a predictor of future cardiovascular events. Our observations, therefore, provide a basis for the observed epidemiological link between RA and atherosclerotic disease.1–4

The mechanisms underlying subclinical atherosclerotic disease in RA remain largely unknown. Firstly, a high prevalence of smokers has been reported in patients with RA.32 For this reason, smoking subjects were not included in our study to avoid confounding factors. Secondly, subjects affected by immunological disorders, including RA and systemic lupus erythematosus, are often characterised by increased levels of homocysteine, an emerging risk factor for cardiovascular diseases.33–35 In RA, raised serum homocysteine levels may be due, at least in part, to methotrexate.36,37 Homocysteine levels in our patients with RA, however, did not differ from those of control subjects, and were not predictive of abnormal FMV. Finally, RA is associated with the evidence of an atherogenic lipid profile with LDL lipoprotein cholesterol concentration,38 and increased levels of LDL cholesterol39 and LP(a) lipoprotein,40 a lipoprotein with prothrombotic action. In our study, patients with RA had higher values of total cholesterol but also of HDL cholesterol than controls. This may be partially explained by corticosteroid treatment, which has been associated with an increase in HDL cholesterol concentrations.41 However, the fact that in our series HDL levels in the 19 patients not treated with steroids were significantly higher than those in controls and only slightly lower than, but not significantly different from, the levels of the 13 steroid treated subjects suggests that other factors may also be implicated in this enhancement.

In this study endothelial dysfunction in RA was related not only to LDL cholesterol levels but also to the inflammatory state. LDL cholesterol is an established risk factor for atherosclerosis in the general population, and its adverse prognostic significance may in part be related to its ability to induce endothelial dysfunction.42–44 Of note, the inflammatory microenvironment promotes the formation of oxidised LDLs which are responsible for oxidative injury of vascular wall.5

This study supports the importance of inflammation as a determinant of endothelial dysfunction. This is in agreement with an increasing body of evidence suggesting that atherosclerosis may be considered a chronic inflammatory disorder.5 Indeed, large amounts of activated inflammatory cells, including monocytes, macrophages, and T lymphocytes, as well as increased expression of leucocyte adhesion molecules, have been documented in atherosclerotic plaques.5 Thus the present observation that the mean CRP level over time is a good predictor of impaired FMV in RA is a valuable finding from a pathogenetic and clinical point of view. CRP, indeed, is a predictor of future myocardial infarction and ischaemic stroke in the general population, even within its normal distribution range.9–11 In RA, cytokines such as interleukin 6 and tumour necrosis factor α modulate the hepatic synthesis of CRP.45–47 At the same time, CRP induces expression on the endothelial surface of adhesion molecules, including vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin, and promotes the adherence of leucocytes with the consequent initiation of vascular atherosclerotic damage.46

In conclusion, this study demonstrated that young to middle aged patients with RA with low disease activity, free from cardiovascular risk factors and overt cardiovascular disease, have an altered endothelial reactivity, which indicates a higher susceptibility to the development of atherosclerotic disease. Although confirming that traditional risk factors, such as LDL cholesterol, may be of importance in determining preclinical atherosclerotic damage in these patients, our results underline the pivotal role of the prolonged inflammatory state as a promoter of cardiovascular disease in RA.


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.